Document:

Exhibit 10.1

 

VNUE,
INC.

 

April 19,
2022

 

ClearTrust,
LLC

16540
Pointe Village Dr, Ste 205

Lutz,
FL 33558

 

Ladies
and Gentlemen:

 

VNUE,
Inc., a Nevada corporation (the “Company”), and GHS Investments, LLC (the “Investor”) have entered into a Securities
Purchase Agreement dated as of April 13, 2022 (the “Agreement”) providing for the issuance of 260 Series B Preferred
Shares (the “Preferred Shares”)

 

You
as Transfer Agent are hereby irrevocably authorized and instructed to reserve a specified number of shares of common stock (“Common
Stock”) of the Company (initially, 167,251,464 shares of Common stock) for issuance upon full conversion of the Preferred Shares
in accordance with the terms thereof. In the event of a stock split, the reserve amount will be automatically adjusted with the same
ratio as the stock split. The amount of Common Stock so reserved may be increased, from time to time, only upon the written instructions
of the Company or the Investor, and not to exceed the “Required Minimum” as noted in the SPA. The Company and Investor
understand that the Transfer Agent will only increase the reserve if authorized unissued shares are available and have not been previously
reserved. Further, conversions will only be processed should there be sufficient unissued, but authorized shares available.

 

The
ability to convert the Preferred Shares in a timely manner is a material obligation of the Company pursuant to the Agreement. You have
the right to rely on each notice of conversion (“Conversion Notice”) as presented, and have no responsibility to verify the
conversion formula used. Provided you are acting as Transfer Agent at the time, your firm is hereby irrevocably authorized and
instructed to within three (3) Trading days issue shares of Common Stock of the Company to the Investor without any further action or
confirmation by the Company upon your receipt from the Investor of: (i) a Conversion Notice executed by the Investor; (ii) any other
supporting documentation reasonably required by the Transfer Agent; (iii) opinion of counsel confirming that the shares to be issued
have been registered and the Registration Statement is currently effective or an opinion of counsel of the Investor or the Company, in
form, substance and scope customary for opinions of counsel in comparable transactions (and satisfactory to the Transfer Agent), to the
effect that the applicable shares of Common Stock are not “restricted securities” as defined in Rule 144 and otherwise
may be issued pursuant to Rule 144 under the Federal Securities Act of 1933, as amended (the “Securities Act”), without
any transfer restrictions; and (iv) customary seller representation letter for sales made under Rule 144 signed by the Investor
if applicable. Such shares should be issued and delivered, at the option of the Investor as specified in the Conversion Notice or similar
instruction either (i) electronically if the Company is approved by The Depository Trust Company (“DTC”) for Deposit Withdrawal
at Custodian (“DWAC”) processing by making the shares available in book-entry form for further credit to the beneficial Investor
account at a participant broker with DTC through its DWAC system, provided the Investor causes its broker or bank to properly initiate
a DWAC deposit, or (ii) in certificated form without any restrictive legend which would restrict the transfer of the shares provided
however that if such shares are not registered for resale under the Securities Act or are not able to be sold under Rule 144 and
you have not received an opinion of counsel that the issuance of the shares is exempt from registration under the Securities Act, then
the issued certificates for such shares shall bear the following restrictive legend:

 

     

     

    

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THE SECURITIES MAY
NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR AN OPINION
OF COUNSEL IN FORM, SUBSTANCE AND SCOPE CUSTOMARY FOR OPINIONS OF COUNSEL IN COMPARABLE TRANSACTIONS AND SATISFACTORY TO THE TRANSFER
AGENT THAT REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.

 

The
unissued shares shall remain in the created reserve with you, the Transfer Agent, until the Investor and an authorized
officer of the Company provide written instructions to you that the shares or any part of them shall be taken out of the reserve and
shall no longer be subject to the terms of these instructions. In the event the Company delivers to ClearTrust, LLC and the Investor
written “Notice to Vacate the Reserve” and the Investor does not respond within 10 calendar days to such notice, the Company
and Transfer Agent will assume the Investor is in agreement with said notice and will take the shares or any part of them out of the
reserve at the end of said 10 days, and the Transfer Agent shall no longer be subject to the terms of these instructions for any shares
removed from the reserve. Written notice must be sent by the issuer via certified mail to the address of record for the Investor or by
email to the Investor’s email address as stated in the last notice of conversion presented.

 

The
Company shall indemnify you and your officers, directors, principals, partners, agents and representatives, and hold each of them harmless
from and against any and all loss, liability, damage, claim or expense (including the reasonable fees and disbursements of its attorneys)
incurred by or asserted against you or any of them arising out of or in connection with the instructions set forth herein, the performance
of your duties hereunder and otherwise in respect hereof, including the costs and expenses of defending yourself or themselves against
any claim or liability hereunder. Such indemnification includes any claim made by the Company against you with respect to these instructions
or the performance of your duties hereunder. You shall have no liability to the Company in respect of this, and you shall be entitled
to rely in this regard on the advice of counsel.

 

The
Board of Directors of the Company has approved the foregoing IRREVOCABLE INSTRUCTIONS. Company hereby confirms to you that no instruction
other than as contemplated herein will be given to you by Company with respect to the matters referenced herein. Company hereby authorizes
you, and you shall be obligated, to disregard any contrary instruction received by or on behalf of Company or any other person purporting
to represent Company. At your sole discretion, you are also authorized to release any information you deem necessary towards the processing,
clearing, and settlement of the shares arising from this reservation.

 

    2

     

    

 

Notwithstanding
any other provision hereof, Company and Investor understand that you shall not be required to perform any issuance or transfer of Conversion
Shares if (i) such an issuance or transfer of Conversion Shares is in violation of any state or federal securities laws or regulations,
or (ii) the issuance or transfer of Conversion Shares is prohibited or stopped as required or directed by an order of a court of competent
jurisdiction. Additionally, Company and Investor understand that you shall not be required to perform any issuance or transfer of Common
Stock if Company is in default of its payment obligations under its transfer agent service agreement (“the TA Agreement”)
with you; provided, however, that in such case Investor shall have the right to pay the obligations in default or otherwise resolve the
deficiency in a manner satisfactory to the Transfer Agent. The Investor is responsible for all fees associated with the Conversion Notice,
including but not limited to the issuance, delivery and transfer of shares, and acknowledges you will not act on a Conversion Notice
without payment of fees owed.

 

The
Company agrees that in the event that you resign or are terminated as the Company’s Transfer Agent, the Company shall engage a
suitable replacement agent that will agree to serve as agent for the Company within five (5) business days. You reserve the right to
resign as Transfer Agent at any time in accordance with the terms of your TA Agreement with the Company, and upon either voluntary resignation
or termination by the Company, your obligations under this letter shall cease immediately and you shall have no further obligations to
act under these instructions. Notwithstanding the forgoing, the Company acknowledges that you will complete any pending conversion request
that is outstanding at the time of termination by either party.

 

This
letter is governed by the laws of the state of Florida.

 

The
Investor is intended to be and is a third party beneficiary hereof, and no amendment or modification to the instructions set forth herein
may be made without the consent of the Investor.

 

[Signature
Page Follows]

 

    3

     

    

 

	 	 	 	Very truly yours,
	 	 	 	 	 
	 	 	 	VNUE, INC.
	 	 	 	 	 
	 	 	 	By:	 
	 	 	 	Name:	Zach Bair
	 	 	 	Title:	CEO
	 	 	 	 	 
	Acknowledged and Agreed:	 	 	 
	GHS INVESTMENTS, LLC	 	 	 
	 	 	 	 	 
	By:	 	 		 
	Name:	 	 	 	 
	Title:	 	 	 	 
	 	 	 	 	 
	Acknowledged and Agreed:	 	 	 
	CLEARTRUST, LLC	 	 	 
	 	 	 	 	 
	By:	 	 		 
	Name:	 	 	 	 
	Title:	 	 	 	 

 

    4Exhibit 4.2
	​

	[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential.

​
Supplemental Agreement and First Amendment to
License Agreement regarding NEFECONTM
between
Calliditas Therapeutics AB (Publ)
and
Everest Medicines II Limited
This SUPPLEMENTAL AGREEMENT AND FIRST AMENDMENT TO THE LICENSE AGREEMENT REGARDING NEFECONTM (this “First Amendment”) is made and entered into by and between Calliditas Therapeutics AB (Publ), corp. reg. no. 556659-9766, with a registered office at PO Box 70351, SE-107 24 Stockholm, Sweden (“Licensor” or “Calliditas”), and Everest Medicines II Limited, an exempted company organized and existing under the laws of Cayman Islands, with a registered office at Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 (“Licensee”). Licensor and Licensee may be referred herein individually as a “Party”, and collectively as the “Parties”.
WITNESSETH:
		WHEREAS, 
	Licensor and Licensee are parties to a License Agreement regarding NEFECON(R) dated as of June 10, 2019 (the “Agreement”);

		WHEREAS, 
	the Agreement sets forth certain rights and obligations of both Parties;

		WHEREAS, 
	the Parties wish to amend the Agreement to provide for certain modifications in order to extend the territory covered by the collaboration between both Parties to include South Korea in accordance with Section 5 of the Agreement (the “Territory Extension”); and

		WHEREAS, 
	Licensee and Licensor desire to accordingly amend the Agreement as further described below.

NOW, THEREFORE, in consideration of the premises and covenants set forth herein, and intending to be legally bound hereby, the Parties hereto agree as follows:
Capitalized terms used in this First Amendment without definition shall have the respective meanings assigned to them in the Agreement.
		1.
	Section 2.44 of the Agreement is hereby amended in its entirety to read as follows:

“2.44 “Territory” means (i) Greater China, including Mainland China, Taiwan, Hong Kong and Macau, (ii) Singapore, (iii), effective as of March 7, 2022, South Korea and (iv) any additional geographical territories agreed between the Parties in accordance with Section 5.”
​

1

		2.
	Section 3.4 of the Agreement is hereby amended by adding at the end the following provisions:

“Notwithstanding the above, for South Korea, Licensee shall maintain control over pricing, reimbursement and approval of marketing material for the commercialization of the Product until [**].”
		3.
	In Section 7.7 of the Agreement the table is hereby amended by adding at the end the following row:

“
	[**]
	[**] 

.”
		4.
	Section 7.8 of the Agreement is hereby amended by adding at the end the following provisions:

“Notwithstanding the above, in the event Licensee fails to meet the Milestone Due Date for the South Korean NDA application submission, Calliditas’ sole remedy shall be to terminate this First Amendment, provided that Licensee may extend the Milestone Due Date until [**] by paying to Calliditas by bank wire transfer of immediately available funds the sum of [**] USD no later than the later of a) [**], or b) [**].
		5.
	Section 9.2.1 of the Agreement is hereby amended in its entirety to read as follows:

“Upon achievement of each of the milestone events set out in the following table (“Milestone Event”) for the Licensed Product, Licensee shall pay to Calliditas the non-refundable, non-creditable amounts set out next to such milestone event in the table (“Milestone Payment”):
	Milestone Event
	Milestone Payment

	Clinical Development Milestones – IgA Nephropathy

	[**]
	[**] USD

	[**]
	[**] USD

	[**]
	[**] USD

	[**]
	[**] USD

	[**]
	[**] USD

	[**]
	[**] USD

	[**]
	[**] USD

	Sub total
	[**] USD

​
​

2

	​
	​

	Clinical Development Milestones – Additional Indications (if any)

	[**]
	[**] USD 

	[**]
	[**] USD

	Sub total
	[**] USD

	​
	​

	Commercial Milestones

	For the first year in which trailing 12 months Net Sales for all Licensed Products (i.e. all indications in the Field) exceeds [**] USD in the Territory
	[**] USD

	For the first year in which trailing 12 months Net Sales for all Licensed Products (i.e. all indications in the Field) exceeds [**] USD in the Territory
	[**] USD

	For the first year in which trailing 12 months Net Sales for all Licensed Products (i.e. all indi­cations in the Field) exceeds [**] USD in the Territory
	[**] USD

	For the first year in which trailing 12 months Net Sales for all Licensed Products (i.e. all indications in the Field) exceeds [**] USD in the Territory
	[**] USD

	Sub total
	[**] USD

	​
	​

	Total
	108 million USD

”
		6.
	Section 14.2 of the Agreement is hereby amended by adding at the end the following provisions:

“Notwithstanding the above, Calliditas shall be entitled to invoice to Licensee Calliditas’ actual out-of-pocket costs relating to the prosecution and maintenance of patents for South Korea, such amounts to be invoiced annually with respect to the costs paid in the prior calendar year, beginning in 2023 with respect to costs paid in 2022. Such invoices shall be submitted no later than [**] days of the close of the calendar year to which they relate and shall be paid by Licensee within [**] days after the invoice date by bank wire transfer of
​

3

immediately available funds to such account as is generally used for payments to Calliditas or as Calliditas may designate by notice to Licensee.”
		7.
	In addition to the original upfront payment stipulated in Section 9.1 Upfront Payment of the Agreement, Licensee shall additionally pay to Calliditas the non-refundable, non-deductible amount of 3 million USD within thirty (30) business days upon the full execution of this First Amendment and the receipt of the invoice made by Calliditas, in consideration of such Territory Extension.

		8.
	This First Amendment, together with the Agreement and any Schedules thereto, constitute the entire agreement between the Parties with respect to the subject matter contained therein, and together, supersede and replace any and all prior and contemporaneous understandings, arrangements and agreements, whether oral or written, with respect to the subject matter.

		9.
	Except as otherwise amended hereby, the Agreement shall remain in full force and effect as presently written, and the rights, duties, liabilities and obligations of the Parties thereto, as presently constituted, will continue in full effect.

		10.
	This First Amendment may be executed by the Parties on separate counterparts, each of which shall be an original and both of which, taken together, shall constitute one and the same agreement. This First Amendment and any counterpart signature page hereto may be delivered by a Party by facsimile or electronic transmission with the same effect as if such Party had delivered an executed original counterpart of this First Amendment.

[signature page follows]
​

4

IN WITNESS WHEREOF, the Parties have caused this First Amendment to be executed by their duly authorized representatives, effective this 7th day of March, 2022.
​
	​

	​

	Calliditas Therapeutics AB (Publ)
	Everest Medicines II Limited

	​
	​

	By: /s/ Renee Aguiar-Lucander
	By: /s/ Kerry Blanchard

	​
	​

	Name: Renee Aguiar-Lucander
	Name: Kerry Blanchard

	Title: CEO   
	Title: CEO

	​
	​

	Date: March 7, 2022
	Date: March 7, 2022

​

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]